Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04853251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Study acronym: Belvedere
StatusRecruiting
PhasePhase 4
Started2021-12-14
View on ClinicalTrials.gov ↗
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Amendment history 4 changes detected by DataLookout

2026-08-11
Primary completion moved earlier: 2027-09-30 → 2027-07-30
2026-08-11
Completion moved earlier: 2027-10-29 → 2027-08-31
2026-05-13
Primary completion moved earlier: 2028-03-31 → 2027-09-30
2026-05-13
Completion moved earlier: 2028-04-30 → 2027-10-29
Trial Details
NCT Number NCT04853251
Lead Sponsor Genentech, Inc.
Conditions Neovascular Age-related Macular Degeneration
Enrollment 188 participants
Start Date 2021-12-14
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-02